Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CKPT Checkpoint Therapeutics	$4.24 +0.1%	$4.08	$1.75 ▼ $4.50	$368.53M	1.18	1.35 million shs	2.10 million shs
ORIC ORIC Pharmaceuticals	$8.03 +34.5%	$5.33	$3.90 ▼ $14.67	$569.34M	1.37	703,596 shs	9.58 million shs
TCRX TScan Therapeutics	$1.47 +1.0%	$1.38	$1.02 ▼ $9.29	$83.47M	1.06	402,633 shs	167,647 shs
TECX Tectonic Therapeutic	$22.22 +3.1%	$19.35	$13.70 ▼ $61.07	$413.98M	3.44	173,960 shs	36,718 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CKPT Checkpoint Therapeutics	+0.95%	+1.20%	+2.92%	+56.09%	+136.31%
ORIC ORIC Pharmaceuticals	+3.29%	+1.70%	+17.29%	-23.85%	-32.24%
TCRX TScan Therapeutics	+1.40%	+9.85%	-9.38%	-28.22%	-83.41%
TECX Tectonic Therapeutic	0.00%	-4.56%	+6.79%	-15.72%	+2,154,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CKPT Checkpoint Therapeutics	2.4257 of 5 stars	1.2	4.0	4.2	2.7	0.8	0.0
ORIC ORIC Pharmaceuticals	3.6865 of 5 stars	3.5	0.0	4.3	3.0	1.7	0.6
TCRX TScan Therapeutics	3.3124 of 5 stars	4.5	1.0	0.0	2.7	3.3	0.6
TECX Tectonic Therapeutic	2.9822 of 5 stars	3.6	1.0	0.0	2.5	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CKPT Checkpoint Therapeutics	2.33	Hold	$4.33	2.32% Upside
ORIC ORIC Pharmaceuticals	3.00	Buy	$19.17	138.66% Upside
TCRX TScan Therapeutics	3.00	Buy	$7.80	432.42% Upside
TECX Tectonic Therapeutic	3.14	Buy	$79.20	256.44% Upside

Current Analyst Ratings Breakdown

Latest TCRX, ORIC, CKPT, and TECX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	TECX Tectonic Therapeutic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$51.00 ➝ $85.00
5/7/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/6/2025	ORIC ORIC Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $12.00
5/6/2025	ORIC ORIC Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/6/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
5/5/2025	ORIC ORIC Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
4/21/2025	TECX Tectonic Therapeutic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
4/8/2025	TCRX TScan Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/31/2025	CKPT Checkpoint Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.80 ➝ $4.80
3/21/2025	TECX Tectonic Therapeutic	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$112.00 ➝ $101.00
3/20/2025	ORIC ORIC Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CKPT Checkpoint Therapeutics	$41K	8,988.53	N/A	N/A	($0.47) per share	-9.01
ORIC ORIC Pharmaceuticals	N/A	N/A	N/A	N/A	$3.42 per share	N/A
TCRX TScan Therapeutics	$4.42M	18.75	N/A	N/A	$3.15 per share	0.47
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$2.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CKPT Checkpoint Therapeutics	-$51.85M	-$1.29	N/A	∞	N/A	N/A	N/A	-659.07%	8/11/2025 (Estimated)
ORIC ORIC Pharmaceuticals	-$100.70M	-$1.87	N/A	N/A	N/A	N/A	-44.54%	-40.72%	8/11/2025 (Estimated)
TCRX TScan Therapeutics	-$89.22M	-$1.09	N/A	N/A	N/A	-1,188.88%	-58.72%	-36.02%	8/11/2025 (Estimated)
TECX Tectonic Therapeutic	$12.16M	-$7.31	N/A	N/A	N/A	N/A	-35.53%	-31.97%	8/13/2025 (Estimated)

Latest TCRX, ORIC, CKPT, and TECX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CKPT Checkpoint Therapeutics	-$0.10	-$0.19	-$0.09	-$0.19	$4.53 million	N/A
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A
5/5/2025	Q1 2025	ORIC ORIC Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A
3/28/2025	Q4 2024	CKPT Checkpoint Therapeutics	-$0.22	-$0.69	-$0.47	-$0.69	N/A	$0.04 million
3/20/2025	Q4 2024	TECX Tectonic Therapeutic	-$1.39	-$0.84	+$0.55	-$0.84	N/A	N/A
3/5/2025	Q4 2024	TCRX TScan Therapeutics	-$0.27	-$0.29	-$0.02	-$0.30	$1.43 million	$0.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CKPT Checkpoint Therapeutics	N/A	N/A	N/A	N/A	N/A
ORIC ORIC Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CKPT Checkpoint Therapeutics	N/A	0.29	0.29
ORIC ORIC Pharmaceuticals	N/A	10.56	13.15
TCRX TScan Therapeutics	0.13	9.56	9.56
TECX Tectonic Therapeutic	N/A	9.39	9.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CKPT Checkpoint Therapeutics	22.00%
ORIC ORIC Pharmaceuticals	95.05%
TCRX TScan Therapeutics	82.83%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
CKPT Checkpoint Therapeutics	2.10%
ORIC ORIC Pharmaceuticals	6.82%
TCRX TScan Therapeutics	4.35%
TECX Tectonic Therapeutic	38.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CKPT Checkpoint Therapeutics	10	87.02 million	47.81 million	Optionable
ORIC ORIC Pharmaceuticals	80	71.09 million	67.09 million	Optionable
TCRX TScan Therapeutics	100	56.59 million	51.90 million	Not Optionable
TECX Tectonic Therapeutic	120	18.67 million	13.40 million	N/A

TCRX, ORIC, CKPT, and TECX Headlines

Recent News About These Companies

Woodline Partners LP Has $6.01 Million Holdings in Tectonic Therapeutic (NASDAQ:TECX)

May 26 at 4:37 AM | marketbeat.com

29,702 Shares in Tectonic Therapeutic (NASDAQ:TECX) Purchased by Jane Street Group LLC

May 22, 2025 | marketbeat.com

Promising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45

May 22, 2025 | tipranks.com

Soleus Capital Management L.P. Makes New Investment in Tectonic Therapeutic (NASDAQ:TECX)

May 21, 2025 | marketbeat.com

Tectonic Therapeutic Announces Phase 1b Trial Results

May 19, 2025 | tipranks.com

Promising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic Therapeutic

May 19, 2025 | tipranks.com

Tectonic Therapeutic (NASDAQ:TECX) Given Average Rating of "Buy" by Analysts

May 19, 2025 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)

May 17, 2025 | theglobeandmail.com

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in ...

May 17, 2025 | gurufocus.com

Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in Group 2 Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction

May 17, 2025 | quiverquant.com

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure

May 17, 2025 | investing.com

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

May 17, 2025 | globenewswire.com

Paradigm Biocapital Advisors LP Takes $22.40 Million Position in Tectonic Therapeutic (NASDAQ:TECX)

May 16, 2025 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Receives Consensus Recommendation of "Buy" from Analysts

May 16, 2025 | marketbeat.com

Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?

May 13, 2025 | zacks.com

Tectonic Therapeutic (NASDAQ:TECX) Announces Earnings Results, Beats Expectations By $0.17 EPS

May 12, 2025 | marketbeat.com

Farallon Capital Management LLC Boosts Holdings in Tectonic Therapeutic (NASDAQ:TECX)

May 11, 2025 | marketbeat.com

Balyasny Asset Management L.P. Has $11.40 Million Stock Holdings in Tectonic Therapeutic (NASDAQ:TECX)

May 11, 2025 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Shares Purchased by Barclays PLC

May 9, 2025 | marketbeat.com

Promising Potential of Tectonic Therapeutic’s TX45: Buy Rating Supported by Positive Phase Ib Trial Results and Phase II Prospects

May 8, 2025 | tipranks.com

Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Advance Auto Parts Jumps on Surprise Earnings Beat
By Chris Markoch | May 23, 2025
View Advance Auto Parts Jumps on Surprise Earnings Beat

TCRX, ORIC, CKPT, and TECX Company Descriptions

Checkpoint Therapeutics NASDAQ:CKPT

$4.24 +0.01 (+0.12%)

As of 11:48 AM Eastern

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

ORIC Pharmaceuticals NASDAQ:ORIC

$8.03 +2.06 (+34.52%)

As of 11:48 AM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

TScan Therapeutics NASDAQ:TCRX

$1.46 +0.02 (+1.03%)

As of 11:46 AM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Tectonic Therapeutic NASDAQ:TECX

$22.22 +0.67 (+3.11%)

As of 11:47 AM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time